

Dhivya Prabhakar, MD is a board-certified medical oncologist and hematologist providing comprehensive care for patients with cancer and blood disorders at Northwest Georgia Oncology Centers, P.C. Dr. Prabhakar combines extensive clinical experience with a dedication to delivering evidence-based, patient-centered treatment.

She completed her internal medicine residency and hematology/oncology fellowship at University Hospitals Case Medical Center in Cleveland, Ohio, followed by an additional fellowship at The Ohio State University in Columbus, Ohio. She is board certified in internal medicine, medical oncology, and hematology. Prior to joining Northwest Georgia Oncology Centers, Dr. Prabhakar served as an Oncology Attending and Clinical Assistant Professor of Medicine at City of Hope Cancer Center Atlanta, and as Clinical Assistant Professor at the University of Iowa Hospital and Assistant Professor at the Iowa City VA Medical Center.

Dr. Prabhakar provides personalized oncology care at NGOC's Spalding Medical Center is a facility located in Griffin, GA.

EDUCATION:

M.B.B.S., 10/2002 - 10/2008
PES Institute of Medical Science and Research, India

POSTDOCTORAL TRAINING:

Internal Medicine Residency

University Hospitals Case Medical Center, Cleveland, Ohio
06/2013 - 06/2016

Hematology/Oncology Fellowship

University Hospitals Case Medical Center, Cleveland, Ohio
07/2016 - 06/2017

Hematology/Oncology Fellowship

The Ohio State University, Columbus, Ohio

07/2017 – 06/2019

LICENSURE AND CERTIFICATIONS:

State of Georgia, Physician License #95235
National Provider Number (NPI): 1790114270

American Board of Internal Medicine, Internal Medicine (2016)
American Board of Internal Medicine, Medical Oncology (2019)
American Board of Internal Medicine, Hematology (2022)

WORK HISTORY:

Private Practice, Medical Oncology & Hematology
Northwest Georgia Oncology Centers, PC
Griffin, GA
08/2025 – Present

Oncology Attending
Clinical Assistant Professor of Medicine
City of Hope Cancer Center Atlanta
Newnan, GA
05/2023 – 7/2025

Clinical Assistant Professor
University of Iowa Hospital
Iowa city, IA
10/2019 – 04/2023

Assistant Professor
Iowa City VA Medical Center
Iowa city, IA
10/2019 – 04/2023

PROFESSIONAL SOCIETIES:

American Society of Clinical Oncology (ASCO) – Associate Member (2015)
American Society of Hematology (ASH)- Associate Member (2016)
American Medical Association (AMA) - Resident Member
American College of Physicians (ACP) - Resident Member

PRESENTATIONS:

National presentations:

1. Current smoking increases the risk of triple negative breast cancer. **2015**
Prabhakar D, Harris L, Thompson C (Poster Presentation) Annual Meeting, American Society of Clinical Oncology (ASCO) Chicago, Illinois.
2. Non-healing esophageal ulcer secondary to actinomycosis. **2013**
Prabhakar D, Khanal R, Chak A (Poster Presentation) Annual Meeting American College of Physicians, Orlando FL
3. Polymorphic ventricular tachycardia: Deciphering the varying etiology and management based on QTc interval. (Poster Presentation) **2012**
Prabhakar D, Choudhary G, Balakrishnan S, Lakshmanadoss U 10th Annual AMA Research Symposium, Honolulu, Hawaii
4. Keeping the eyes (ECG calipers) wide open in a case of fever- A simple tool in diagnosis of a devastating disease. (Poster Presentation) **2012**
Balakrishnan S, Choudhary G, **Prabhakar D**, Lakshmanadoss U 10th Annual AMA Research Symposium, Honolulu, Hawaii.

Institutional Presentations:

1. Current Smoking Increases the Risk of Triple Negative Breast Cancer **2015**
Poster Presentation at Department of medicine Research day University Hospitals Case Medical Center, Cleveland, OH.
2. Routine Serum Folate testing in outpatient clinics: – Single Institution Experience. Poster Presentation **2015**
Louis Stokes Cleveland Medical Center, Cleveland, OH.
3. Management of Acute Pancreatitis **2008**
Surgical Journal Club at PES medical college, India

Peer Reviewed Publications:

1. Celiac Axis Compression Syndrome: A Syndrome of Delayed Diagnosis? **Prabhakar D**, Venkat D, Cooper GS. Gastroenterol Hepatol (N Y). 2017 Mar;13(3):192-194. PMID: 28539849

2. Polymorphic Ventricular Tachycardia Caused by Normal and Prolonged QT interval with Different Etiologies. **Prabhakar D**, Ayyappan S, Lakshmanadoss U. Journal of medical research and practice. September 2012
3. Retrospective Multicenter Study Comparing Thrombosis Risk in Chinese Versus AfricanAmerican patients with Multiple Myeloma. Raghupathy R, Ayyappan S, **Prabhakar D**, Campagnaro E, Mo F, Wa L, Hui E, R Chan A, Lei K. Br J Haematol. 2017Jan;176(2):315-317. PMID: 2681416

Review Articles:

1. Epidermal Growth Factor Receptor (EGFR)-Targeted Therapies in Esophagogastric Cancer. Ayyappan S, **Prabhakar D**, Sharma N. Anticancer Res. 2013 Oct; 33 (10): 4139-55. PMID: 2412297.
2. Neoadjuvant -Modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection Wolfe A , **Prabhakar D**, Noonan A ,Williams TM Cancer Med 2020 Jul;9(13):4711-4723 . PMID: 32415696

Book Chapter:

1. **Prabhakar D**, Thompson C, Harris L - Blood Markers in Breast Cancer Management. In: Molecular Pathology of Breast Cancer, Sunil Badve ed . Springer Press – 2017

Abstracts:

1. Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis Ayyappan S, Covut F, **Prabhakar D**, Gupta V, Malek E, Metheny L, Tomlinson B, Creger R, Cooper B, Hillard M Lazarus HM,Lima M and Paolo Caimi P. Blood 2017 130: 2842
2. Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes. Ayyappan S, **Prabhakar D**, Gupta V, Cooper B , Lazarus H , De Lima M, Caimi P. Blood 2015 126:3968
3. Current smoking increases the risk of triple negative breast cancer. **Prabhakar D**, Harris L, Thompson C. J Clin Oncol 33, 2015 (suppl; abstr 1592)

4. Retrospective Study of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma. Raghupathy R, Ayyappan S, **Prabhakar D**, MoF, Campagnaro E, Lei K. Blood Journal Nov 2013;122 (21)
5. TGF-beta signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC). Williams N, Varadan V, Vadodkar A, Miskimen K, Gilmore H, Beckloff N, Edelheit S, **Prabhakar D**, Janevski A, Banerjee N, Kamalakaran S, Abu-Khalaf M, Sikov W, Dimitrova N, Harris L. J Clin Oncol 31, 2013 (suppl; abstr 1046)

Dhivya Prabhakar, MD
August 23, 2025